FDA Inspection
AndersonBrecon Inc.AndersonBrecon Inc. – FDA Inspection, Aug 6, 2026
Record Details
This FDA Inspection record concerns AndersonBrecon Inc., with an inspection on August 6, 2026, issued by the Chicago District Office, covering biologics.
- Office
- Chicago District Office
- Person
View Company Profile
ID · 65d9111f-80a9-46a6-a54e-d68b0eca8df8
Inspection Facts
- Inspection number
- 1314012
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.22(d)Procedures not in writing, fully followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of AndersonBrecon Inc.
13| Date | Classification | Office | Project area |
|---|---|---|---|
| August 19, 2026 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 10, 2022 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 4, 2019 | NAI | Center for Devices and Radiological Health | Compliance: Devices |
| December 5, 2018 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| March 23, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for AndersonBrecon Inc.
- FDA Inspection 1295016 - 2026-08-19
- FDA Inspection 1173271 - 2022-06-10
- FDA Inspection 1106253 - 2019-09-04
- FDA Inspection 1077730 - 2018-12-05
- FDA Inspection 1008194 - 2017-03-23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.